These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17697320)

  • 1. MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2.
    Yin H; Glass J; Blanchard KL
    Mol Cancer; 2007 Aug; 6():51. PubMed ID: 17697320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish.
    Zhuravleva J; Paggetti J; Martin L; Hammann A; Solary E; Bastie JN; Delva L
    Br J Haematol; 2008 Nov; 143(3):378-82. PubMed ID: 18729850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A further case of acute myeloid leukaemia with inv(8)(p11q13) and MOZ-TIF2 fusion.
    Billio A; Steer EJ; Pianezze G; Svaldi M; Casin M; Amato B; Coser P; Cross NC
    Haematologica; 2002 May; 87(5):ECR15. PubMed ID: 12010678
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2.
    Liang J; Prouty L; Williams BJ; Dayton MA; Blanchard KL
    Blood; 1998 Sep; 92(6):2118-22. PubMed ID: 9731070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase.
    Champagne N; Pelletier N; Yang XJ
    Oncogene; 2001 Jan; 20(3):404-9. PubMed ID: 11313971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the MOZ-TIF2 oncoprotein in mice represses senescence.
    Largeot A; Perez-Campo FM; Marinopoulou E; Lie-a-Ling M; Kouskoff V; Lacaud G
    Exp Hematol; 2016 Apr; 44(4):231-7.e4. PubMed ID: 26854485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP.
    Deguchi K; Ayton PM; Carapeti M; Kutok JL; Snyder CS; Williams IR; Cross NC; Glass CK; Cleary ML; Gilliland DG
    Cancer Cell; 2003 Mar; 3(3):259-71. PubMed ID: 12676584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes.
    Smolko AE; Sullivan DW; Olsen SN; Kang H; Whedon SD; Baell JB; Cole PA; Armstrong SA; Kuroda MI
    Proc Natl Acad Sci U S A; 2024 Jun; 121(26):e2405905121. PubMed ID: 38889153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.
    Kindle KB; Troke PJ; Collins HM; Matsuda S; Bossi D; Bellodi C; Kalkhoven E; Salomoni P; Pelicci PG; Minucci S; Heery DM
    Mol Cell Biol; 2005 Feb; 25(3):988-1002. PubMed ID: 15657427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Childhood acute myeloid leukemia with hemophagocytosis by the blasts and inv(8)(p11q13) with MOZ-TIF2 fusion transcripts.
    Abdelhaleem M; Shago M; Beimnet K; Sayeh E; Bartakke S; Weitzman S
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):643-5. PubMed ID: 17805042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MOZ fusion proteins in acute myeloid leukaemia.
    Troke PJ; Kindle KB; Collins HM; Heery DM
    Biochem Soc Symp; 2006; (73):23-39. PubMed ID: 16626284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators.
    Collins HM; Kindle KB; Matsuda S; Ryan C; Troke PJF; Kalkhoven E; Heery DM
    J Biol Chem; 2006 Jun; 281(25):17124-17133. PubMed ID: 16613851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of nuclear receptors and cofactors in human endometrium and myometrium.
    Vienonen A; Miettinen S; Bläuer M; Martikainen PM; Tomás E; Heinonen PK; Ylikomi T
    J Soc Gynecol Investig; 2004 Feb; 11(2):104-12. PubMed ID: 14980312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia.
    Carapeti M; Aguiar RC; Goldman JM; Cross NC
    Blood; 1998 May; 91(9):3127-33. PubMed ID: 9558366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.
    Shima H; Yamagata K; Aikawa Y; Shino M; Koseki H; Shimada H; Kitabayashi I
    Int J Hematol; 2014 Jan; 99(1):21-31. PubMed ID: 24258712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MOZ and MOZ-CBP cooperate with NF-kappaB to activate transcription from NF-kappaB-dependent promoters.
    Chan EM; Chan RJ; Comer EM; Goulet RJ; Crean CD; Brown ZD; Fruehwald AM; Yang Z; Boswell HS; Nakshatri H; Gabig TG
    Exp Hematol; 2007 Dec; 35(12):1782-92. PubMed ID: 17920756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13).
    Carapeti M; Aguiar RC; Watmore AE; Goldman JM; Cross NC
    Cancer Genet Cytogenet; 1999 Aug; 113(1):70-2. PubMed ID: 10459350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [FGFR1 and MOZ, two key genes involved in malignant hemopathies linked to rearrangements within the chromosomal region 8p11-12].
    Pébusque MJ; Chaffanet M; Popovici C; Birnbaum D
    Bull Cancer; 2000 Dec; 87(12):887-94. PubMed ID: 11174118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2.
    Aikawa Y; Katsumoto T; Zhang P; Shima H; Shino M; Terui K; Ito E; Ohno H; Stanley ER; Singh H; Tenen DG; Kitabayashi I
    Nat Med; 2010 May; 16(5):580-5, 1p following 585. PubMed ID: 20418886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations.
    Strehl S; Nebral K; König M; Harbott J; Strobl H; Ratei R; Struski S; Bielorai B; Lessard M; Zimmermann M; Haas OA; Izraeli S
    Clin Cancer Res; 2008 Feb; 14(4):977-83. PubMed ID: 18281529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.